10-Q: Caribou Biosciences Reports Q3 2025 Results, Advances CAR-T Programs

Caribou Biosciences reported a net loss of $27.5 million for Q3 2025, alongside positive clinical data for vispa-cel and CB-011, and strategic pipeline prioritization.

Summary

• Net loss for the three months ended September 30, 2025, was $(27.5) million, an improvement from $(34.7) million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $(121.6) million, compared to $(113.6) million for the same period in 2024.
• The accumulated deficit as of September 30, 2025, reached $570.0 million.
• Cash, cash equivalents, and marketable securities totaled $159.2 million as of September 30, 2025, which management expects to fund operations for at least the next 12 months.
• Licensing and collaboration revenue increased to $2.2 million for Q3 2025 from $2.0 million in Q3 2024, but decreased to $7.2 million for the nine months ended September 30, 2025, from $7.9 million in the prior year period.
• Research and development (R&D) expenses decreased by $8.0 million to $22.4 million for Q3 2025 and by $14.1 million to $85.6 million for the nine months ended September 30, 2025, compared to the respective prior year periods.
• General and administrative (G&A) expenses decreased by $0.6 million to $9.2 million for Q3 2025 and by $6.6 million to $29.3 million for the nine months ended September 30, 2025, compared to the respective prior year periods.
• Impairment charges of $12.2 million were recorded for the nine months ended September 30, 2025, related to leased office/lab space and lab equipment due to strategic pipeline prioritization.
• An impairment of equity investment of $9.2 million related to Edge Animal Health was recorded for the nine months ended September 30, 2025.
• Strategic pipeline prioritization, announced on April 24, 2025, led to the discontinuation of the GALLOP phase 1 trial (lupus) and AMpLify phase 1 clinical trial (acute myeloid leukemia), and a workforce reduction of 47 employees (approximately 32%).
• Vispa-cel (CB-010) ANTLER phase 1 clinical trial in relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL) showed an 82% overall response rate (ORR), a 64% complete response (CR) rate, and 51% progression-free survival (PFS) at 12 months in a 22-patient confirmatory cohort.
• An optimized profile cohort of 35 vispa-cel patients achieved an 86% ORR, a 63% CR rate, and 53% PFS at 12 months.
• CB-011 CaMMouflage phase 1 trial in relapsed or refractory multiple myeloma (r/r MM) demonstrated a 92% ORR, a 75% CR/stringent CR (sCR) rate, and 91% minimal residual disease (MRD) negativity in a 12-patient cohort treated with the recommended dose for expansion (RDE).
• The Exclusive License Agreement with Memorial Sloan Kettering Cancer Center (MSKCC) was terminated effective August 11, 2025, following the discontinuation of the CB-012 program.
• A putative class action lawsuit and consolidated shareholder derivative complaints were both voluntarily dismissed without prejudice in April and October 2025, respectively.

Sentiment

Score: 7

Explanation: The company reported strong positive clinical data for its lead CAR-T programs, vispa-cel and CB-011, which are significant milestones in a competitive field. Strategic pipeline prioritization and workforce reductions have led to decreased operating expenses and an improved net loss for the quarter. The dismissal of legal proceedings also removes uncertainty. However, the company continues to incur substantial net losses and negative cash flows from operations, necessitating future capital raises, and faces ongoing risks associated with clinical development and regulatory approval.

Positives

• Positive clinical data for vispa-cel (CB-010) in the ANTLER phase 1 trial, with an 82% ORR and 64% CR rate at 12 months in the confirmatory cohort, and an 86% ORR and 63% CR rate at 12 months in the optimized profile cohort, indicating strong efficacy.
• Highly encouraging clinical data for CB-011 in the CaMMouflage phase 1 trial, showing a 92% ORR, 75% CR/sCR rate, and 91% MRD negativity in the selected cohort.
• Vispa-cel has received Regenerative Medicine Advanced Therapy (RMAT) designation for r/r LBCL and Fast Track designation for r/r B-NHL from the U.S. Food and Drug Administration (FDA).
• CB-011 has received Fast Track designation for r/r MM from the FDA.
• Net loss for the third quarter of 2025 improved to $(27.5) million from $(34.7) million in the prior year quarter.
• Significant reductions in operating expenses, with R&D decreasing by $8.0 million in Q3 2025 and G&A decreasing by $0.6 million in Q3 2025, reflecting successful cost reduction initiatives.
• Cash used in operating activities decreased to $(90.2) million for the nine months ended September 30, 2025, from $(102.7) million for the same period in 2024, indicating improved operational cash burn.
• All legal proceedings, including a class action lawsuit and shareholder derivative complaints, were voluntarily dismissed without prejudice, removing significant legal uncertainties.

Negatives

• Increased net loss for the nine months ended September 30, 2025, to $(121.6) million, compared to $(113.6) million for the same period in 2024.
• Accumulated deficit of $570.0 million as of September 30, 2025, highlighting a history of operating losses.
• Negative cash flow from operations of $(90.2) million for the nine months ended September 30, 2025.
• Licensing and collaboration revenue decreased by $0.7 million for the nine months ended September 30, 2025, primarily due to a $1.6 million decrease from Edge Animal Health.
• Recorded $12.2 million in impairment charges for the nine months ended September 30, 2025, related to leased office/lab space and lab equipment due to reduced usage.
• Incurred a $9.2 million impairment of equity investment related to Edge Animal Health for the nine months ended September 30, 2025, fully impairing the investment.
• Discontinuation of two clinical programs, GALLOP phase 1 trial and AMpLify phase 1 clinical trial, as part of strategic pipeline prioritization.
• Workforce reduction of 47 employees, representing approximately 32% of the workforce, indicating significant restructuring.
• Cash, cash equivalents, and marketable securities decreased from $249.4 million at December 31, 2024, to $159.2 million at September 30, 2025.

Risks

• The company has incurred operating losses and negative cash flows from operations since inception and had an accumulated deficit of $570.0 million as of September 30, 2025.
• Ability to achieve and sustain profitability depends on the successful development, regulatory approval, and commercialization of product candidates and generating sufficient revenue.
• Expects to continue incurring substantial losses and will need to raise additional capital until profitability is achieved.
• Expenses are anticipated to increase substantially as clinical trials advance, regulatory approvals are sought, manufacturing capabilities expand, and additional personnel are hired.
• The successful development of CAR-T product candidates is highly uncertain, with risks including delays, challenges, or issues associated with clinical trials (e.g., failure to meet endpoints, differing interpretations of data, safety issues).
• There is no assurance of succeeding in achieving regulatory approval for any product candidates.
• Dependence on contract manufacturing organizations (CMOs) for manufacturing clinical trial materials, with potential future decision to build own manufacturing facility.
• Risk of not remaining in compliance with Nasdaq continued listing requirements, such as the Minimum Bid Price Rule, which could lead to delisting.
• A reverse stock split, if implemented, may not increase the stock price for a sustained period or ensure compliance with Nasdaq listing requirements, and could be viewed negatively by investors.
• If a reverse stock split is implemented and the stock price drops below $1.00 within one year, immediate delisting may occur without an opportunity to regain compliance.
• The effective increase in authorized shares as a result of a reverse stock split may lead to dilution for existing stockholders from future issuances of shares for capital-raising or other corporate purposes.
• Dependence on equity financing, debt financing, collaborations, and licensing arrangements to fund operating expenses, including the planned vispa-cel pivotal trial.
• No assurance of obtaining adequate financing on acceptable terms, which could lead to significant delays, reductions, or discontinuation of product development and commercialization.
• Disruptions and volatility in global and domestic capital markets (e.g., inflation, tariffs, interest rate fluctuations, geopolitical events) may increase the cost of capital and limit access to capital.

Future Outlook

The company expects to continue incurring substantial losses and will need to raise additional capital until profitability is achieved. It anticipates evaluating vispa-cel in a randomized, controlled pivotal phase 3 clinical trial in approximately 250 2L LBCL CD19-naive patients who are ineligible for transplant and autologous CAR-T cell therapy, with intentions to further refine the trial design through continued engagement with the FDA. Management believes this approach provides a straightforward regulatory path to full FDA approval for vispa-cel, though it cannot assure that the FDA will not request additional requirements. Expenses are expected to increase substantially as clinical trials advance, regulatory approvals are sought, manufacturing capabilities expand, and additional personnel are hired. The company will remain dependent on equity financing, debt financing, collaboration and licensing arrangements, and/or other forms of capital raises to fund operating expenses, including the planned vispa-cel pivotal trial. The 'One Big Beautiful Bill Act' is not expected to have a material impact on consolidated financial statements, and no additional material restructuring charges are expected as the strategic pipeline prioritization was substantially completed in Q2 2025.

Management Comments

• "Management expects that existing cash, cash equivalents, and marketable securities of $159.2 million as of September 30, 2025, will be sufficient to fund our current operating plan for at least the next 12 months from the date this Quarterly Report on Form 10-Q is filed."
• "We anticipate evaluating vispa-cel in a randomized, controlled pivotal phase 3 clinical trial in approximately 250 2L LBCL CD19-nave patients who are ineligible for transplant and autologous CAR-T cell therapy."
• "We intend to further refine our pivotal trial design through continued engagement with the FDA prior to initiation of this pivotal trial."
• "Although we believe this approach provides a straightforward regulatory path to full FDA approval of vispa-cel based on FDA interactions to date, we cannot assure you that, in future discussions with the FDA, the FDA will not recommend or request additional requirements for our planned pivotal phase 3 clinical trial design for vispa-cel."
• "We have selected the 450x10^6 viable CAR-T cell dose with the selected LD regimen as our recommended dose for expansion (RDE) for CB-011."
• "We currently do not expect to record additional material charges [related to restructuring] as our strategic pipeline prioritization was substantially completed in the second quarter of 2025."

Industry Context

Caribou Biosciences operates in the highly competitive and capital-intensive CRISPR genome-editing biopharmaceutical sector, focusing on allogeneic CAR-T cell therapies. The positive early-stage clinical data for vispa-cel and CB-011, particularly the high ORR and CR rates, position the company favorably against competitors in the allogeneic CAR-T space, which aims to overcome limitations of autologous therapies (e.g., manufacturing time, patient access). The strategic pipeline prioritization reflects a broader industry trend of companies focusing resources on their most promising assets to extend runway and achieve key milestones, especially in a challenging funding environment. The FDA's RMAT and Fast Track designations for their lead candidates indicate recognition of their potential to address unmet medical needs, aligning with regulatory efforts to accelerate innovative therapies.

Comparison to Industry Standards

• The 82% ORR and 64% CR rate for vispa-cel in 2L LBCL patients are competitive with or exceed some reported outcomes for autologous CAR-T therapies like Yescarta (axicabtagene ciloleucel) and Kymriah (tisagenlecleucel) in similar patient populations, which typically show ORRs in the 50-80% range and CRs in the 40-60% range in relapsed/refractory settings.
• The 92% ORR and 75% CR/sCR rate for CB-011 in r/r MM patients are highly encouraging, potentially comparing favorably to existing BCMA-targeted therapies, including autologous CAR-T therapies like Abecma (idecabtagene vicleucel) and Carvykti (ciltacabtagene autoleucel), which have demonstrated high response rates (ORR 70-98%, CR/sCR 28-80%) in heavily pretreated multiple myeloma. The allogeneic nature of CB-011 could offer significant advantages in accessibility and speed of treatment over these autologous counterparts.
• The company's focus on "optimized profile" (young donors, partial HLA matching) for vispa-cel reflects an evolving understanding in the allogeneic CAR-T field to enhance efficacy and durability, addressing a key challenge for off-the-shelf approaches.

Management Changes

Corporate Governance

Legal Proceedings

• A putative class action lawsuit, Saylor v. Caribou Biosciences, Inc., et al., filed on December 24, 2024, alleging violations of Sections 10(b) and 20(a) of the Exchange Act regarding disclosures on vispa-cel's safety, efficacy, durability, clinical results, commercial prospects, and financial statements, was voluntarily dismissed without prejudice on April 27, 2025.
• Two shareholder derivative complaints, Moisio, derivatively on behalf of Caribou Biosciences, Inc. v. Haurwitz, et al. (March 3, 2025) and Allen, derivatively on behalf of Caribou Biosciences, Inc. v. Braunstein, et al. (March 11, 2025), were consolidated into In re Caribou Biosciences, Inc. Derivative Litigation. These alleged breach of fiduciary duties by directors and officers related to disclosures challenged in the Saylor Case. The consolidated action was voluntarily dismissed without prejudice on October 17, 2025.

Related Party Transactions

• Recognized $0.6 million of revenue from Pfizer (a related party) for each of the three-month periods ended September 30, 2025, and September 30, 2024, and $1.9 million for each of the nine-month periods ended September 30, 2025, and September 30, 2024, related to an Information Rights Agreement.
• As of September 30, 2025, approximately $1.9 million of related party deferred revenue from Pfizer was included in current liabilities.
• The Exclusive License Agreement for Veterinary Therapeutics with Edge Animal Health (a related party private company) resulted in no revenue recognized in 2025, compared to $1.6 million for the nine months ended September 30, 2024.
• The investment in Edge Animal Health was fully impaired as of June 30, 2025, resulting in a $9.2 million impairment expense for the nine months ended September 30, 2025.

Stakeholder Impact

• Shareholders: Positive clinical data for lead programs could increase investor confidence and potentially stock value. Dismissal of lawsuits reduces legal risk. However, continued net losses, negative cash flow, and the need for future capital raises (potentially dilutive) pose ongoing concerns. A potential reverse stock split could impact perception and liquidity.
• Employees: Workforce reduction of 47 employees (32%) indicates job losses, but strategic prioritization aims to secure the company's future, potentially benefiting remaining employees.
• Customers/Patients: Discontinuation of two clinical programs (GALLOP and AMpLify) means certain patient populations will not receive those potential therapies. However, the focus on vispa-cel and CB-011 aims to accelerate development of promising treatments for r/r B-NHL and r/r MM patients.
• Creditors/Suppliers: Reduced operating expenses and a stated 12-month cash runway provide some stability, but the ongoing need for capital raises highlights financial dependency.
• Regulatory Authorities: Continued engagement with the FDA for pivotal trial design for vispa-cel indicates adherence to regulatory processes and aims for a clear path to approval.

Next Steps

• Further refine the pivotal trial design for vispa-cel through continued engagement with the FDA prior to initiation of the phase 3 trial.
• Advance clinical trials for CAR-T cell therapy product candidates through succeeding clinical phases of development.
• Seek regulatory and marketing approvals for product candidates that successfully complete clinical trials.
• Expand manufacturing capabilities and supply chain capacity for product candidates.
• Hire additional personnel, as needed, to support clinical development efforts.
• Acquire or in-license intellectual property or new technologies.
• Expand, maintain, enforce, and defend the intellectual property portfolio.
• Establish a sales, marketing, and distribution infrastructure to commercialize any product candidates for which marketing approval is obtained.
• Continue to operate as a public company, including defending against any future class action securities litigation and shareholder derivative lawsuits.
• Evaluate the potential impact of the 'One Big Beautiful Bill Act' on deferred taxes and related disclosures.
• Evaluate the impact of ASU 2023-09 (Income Tax Disclosures), ASU 2024-03 (Income Statement Expense Disaggregation), and ASU 2025-06 (Internal-Use Software Accounting).
• Potentially implement a reverse stock split on or prior to June 12, 2026, at the discretion of the board of directors.

Key Dates

Recommendation

The filing presents a mixed but cautiously optimistic picture. The strong clinical data for vispa-cel and CB-011 are significant positives, demonstrating the potential of the CRISPR platform and providing a clear path forward for these lead programs. The strategic pipeline prioritization and associated cost reductions are prudent steps to extend the cash runway and focus resources. The dismissal of legal proceedings also removes a notable overhang. However, the company continues to operate at a substantial loss, has negative cash flow from operations, and will require significant additional capital to fund its pivotal trials and commercialization efforts. The impairment charges and the full impairment of the Edge Animal Health investment highlight past challenges. While the clinical progress is compelling, the financial challenges and the inherent risks of clinical development and regulatory approval warrant a "hold" recommendation for seasoned investors, suggesting monitoring for further progress in clinical trials and clarity on future financing strategies before a more aggressive stance.

Keywords

CRISPR, Genome-editing, CAR-T cell therapy, Allogeneic, Vispa-cel, CB-010, CB-011, Non-Hodgkin lymphoma, Multiple myeloma, Clinical trial, Biopharmaceutical, Oncology, Hematologic malignancies, Biotech, FDA, RMAT, Fast Track, Financial results, 10-Q